Agios Pharmaceuticals, Inc. (AGIO) Now Covered by Royal Bank Of Canada

Royal Bank Of Canada began coverage on shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage issued an outperform rating and a $78.00 price target on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the company. Oppenheimer Holdings, Inc. reaffirmed an outperform rating and issued a $83.00 target price (up previously from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $80.00 target price (up previously from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday, August 8th. Leerink Swann raised Agios Pharmaceuticals from a market perform rating to an outperform rating and raised their target price for the company from $50.00 to $80.00 in a report on Wednesday, August 2nd. Cann reaffirmed a buy rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. Finally, Janney Montgomery Scott reaffirmed a hold rating on shares of Agios Pharmaceuticals in a report on Tuesday, August 1st. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $75.11.

Agios Pharmaceuticals (NASDAQ AGIO) opened at 66.43 on Thursday. The firm has a 50 day moving average price of $60.25 and a 200-day moving average price of $54.45. The firm’s market capitalization is $3.21 billion. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.21). The business had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business’s quarterly revenue was up 62.1% compared to the same quarter last year. During the same period last year, the business earned ($1.47) EPS. On average, equities analysts forecast that Agios Pharmaceuticals will post ($7.07) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Agios Pharmaceuticals, Inc. (AGIO) Now Covered by Royal Bank Of Canada” was first published by BBNS and is owned by of BBNS. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://baseballnewssource.com/markets/agios-pharmaceuticals-inc-agio-now-covered-by-royal-bank-of-canada/1645748.html.

In related news, insider Scott Biller sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $65.00, for a total transaction of $975,000.00. Following the completion of the transaction, the insider now owns 6,264 shares in the company, valued at approximately $407,160. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lewis Clayton Jr. Cantley sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $65.47, for a total value of $65,470.00. Following the transaction, the director now owns 86,394 shares of the company’s stock, valued at approximately $5,656,215.18. The disclosure for this sale can be found here. Insiders sold a total of 104,230 shares of company stock valued at $6,245,972 in the last quarter. Corporate insiders own 10.55% of the company’s stock.

Several institutional investors have recently bought and sold shares of AGIO. Bank of Montreal Can lifted its position in shares of Agios Pharmaceuticals by 11.7% during the 1st quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares during the period. Blue Sky Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the 1st quarter worth approximately $129,000. QS Investors LLC bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $144,000. Russell Investments Group Ltd. lifted its position in shares of Agios Pharmaceuticals by 163.9% during the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares during the period. Finally, Cubist Systematic Strategies LLC lifted its position in shares of Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 3,123 shares during the period. Institutional investors and hedge funds own 94.40% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster


Leave a Reply

 
© 2006-2017 BBNS.